Vascular Endothelial Receptor Tyrosine Phosphatase: Identification of Novel Substrates Related to Junctions and a Ternary Complex with EPHB4 and TIE2

被引:25
作者
Drexler, Hannes C. A. [2 ]
Vockel, Matthias [1 ,4 ]
Polaschegg, Christian [1 ,5 ]
Frye, Maike [1 ,6 ]
Peters, Kevin [3 ]
Vestweber, Dietmar [1 ]
机构
[1] Max Planck Inst Mol Biomed, Dept Vasc Biol, Rontgenstr 20, D-48149 Munster, Germany
[2] Max Planck Inst Mol Biomed, Bioanalyt Mass Spectrometry, Rontgenstr 20, D-48149 Munster, Germany
[3] Aerplo Pharmaceut, Cincinnati, OH 45242 USA
[4] Univ Hosp Munster, Inst Human Genet, D-48149 Munster, Germany
[5] Roche Pharma AG, Emil Barell Str 1, D-79639 Grenzach Wyhlen, Germany
[6] Univ Med Ctr Hamburg UKE, Inst Clin Chem & Lab Med, Martinistr 52, D-20246 Hamburg, Germany
关键词
DIABETIC MACULAR EDEMA; VE-PTP; DOWN-REGULATION; IN-VIVO; C-FES; KINASE; CELLS; INHIBITION; PHOSPHORYLATION; MORPHOGENESIS;
D O I
10.1074/mcp.RA119.001716
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Vascular endothelial protein tyrosine phosphatase (VEPTP, PTPRB) is a receptor type phosphatase that is crucial for the regulation of endothelial junctions and blood vessel development. We and others have shown recently that VE-PTP regulates vascular integrity by dephosphorylating substrates that are key players in endothelial junction stability, such as the angiopoietin receptor TIE2, the endothelial adherens junction protein VE-cadherin and the vascular endothelial growth factor receptor VEGFR2. Here, we have systematically searched for novel substrates of VE-PTP in endothelial cells by utilizing two approaches. First, we studied changes in the endothelial phosphoproteome on exposing cells to a highly VE-PTPspecific phosphatase inhibitor followed by affinity isolation and mass-spectrometric analysis of phosphorylated proteins by phosphotyrosine-specific antibodies. Second, we used a substrate trapping mutant of VE-PTP to pull down phosphorylated substrates in combination with SILAC-based quantitative mass spectrometry measurements. We identified a set of substrate candidates of VE-PTP, of which a remarkably large fraction (29%) is related to cell junctions. Several of those were found in both screens and displayed very high connectivity in predicted functional interaction networks. The receptor protein tyrosine kinase EPHB4 was the most prominently phosphorylated protein on VE-PTP inhibition among those VE-PTP targets that were identified by both proteomic approaches. Further analysis revealed that EPHB4 forms a ternary complex with VE-PTP and TIE2 in endothelial cells. VE-PTP controls the phosphorylation of each of these two tyrosine kinase receptors. Despite their simultaneous presence in a ternary complex, stimulating each of the receptors with their own specific ligand did not cross-activate the respective partner receptor. Our systematic approach has led to the identification of novel substrates of VE-PTP, of which many are relevant for the control of cellular junctions further promoting the importance of VE-PTP as a key player of junctional signaling.
引用
收藏
页码:2058 / 2077
页数:20
相关论文
共 76 条
[1]   Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis [J].
Adams, RH ;
Wilkinson, GA ;
Weiss, C ;
Diella, F ;
Gale, NW ;
Deutsch, U ;
Risau, W ;
Klein, R .
GENES & DEVELOPMENT, 1999, 13 (03) :295-306
[2]   Design and synthesis of potent, non-peptidic inhibitors of HPTPβ [J].
Amarasinghe, Kande K. D. ;
Evidokimov, Artem G. ;
Xu, Kevin ;
Clark, Cynthia M. ;
Maier, Matthew B. ;
Srivastava, Anil ;
Colson, Anny-Odile ;
Gerwe, Gina S. ;
Stake, George E. ;
Howard, Brian W. ;
Pokross, Matthew E. ;
Gray, Jeffrey L. ;
Peters, Kevin G. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (16) :4252-4256
[3]   Vascular endothelial cell-specific phosphotyrosine phosphatase (VE-PTP) activity is required for blood vessel development [J].
Baeumer, Sebastian ;
Keller, Linda ;
Holtmann, Astrid ;
Funke, Ruth ;
August, Benjamin ;
Gamp, Alexander ;
Wolburg, Hartwig ;
Wolburg-Buchholz, Karen ;
Deutsch, Urban ;
Vestweber, Dietmar .
BLOOD, 2006, 107 (12) :4754-4762
[4]  
BARTZ R, 2016, AM J RESP CRIT CARE, V193
[5]   ROCK2 primes the endothelium for vascular hyperpermeability responses by raising baseline junctional tension [J].
Beckers, Cora M. L. ;
Knezevic, Nebojsa ;
Valent, Erik T. ;
Tauseef, Mohammad ;
Krishnan, Ramaswamy ;
Rajendran, Kavitha ;
Hardin, C. Corey ;
Aman, Jurjan ;
van Bezu, Jan ;
Sweetnam, Paul ;
van Hinsbergh, Victor W. M. ;
Mehta, Dolly ;
Amerongen, Geerten P. van Nieuw .
VASCULAR PHARMACOLOGY, 2015, 70 :45-54
[6]   Substrate-trapping techniques in the identification of cellular PTP targets [J].
Blanchetot, C ;
Chagnon, M ;
Dubé, N ;
Hallé, A ;
Tremblay, ML .
METHODS, 2005, 35 (01) :44-53
[7]   VE-PTP inhibition stabilizes endothelial junctions by activating FGD5 [J].
Braun, Laura J. ;
Zinnhardt, Maren ;
Vockel, Matthias ;
Drexler, Hannes C. ;
Peters, Kevin ;
Vestweber, Dietmar .
EMBO REPORTS, 2019, 20 (07)
[8]   Targeting Tie2 for Treatment of Diabetic Retinopathy and Diabetic Macular Edema [J].
Campochiaro, Peter A. ;
Peters, Kevin G. .
CURRENT DIABETES REPORTS, 2016, 16 (12)
[9]   Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression [J].
Campochiaro, Peter A. ;
Khanani, Arshad ;
Singer, Michael ;
Patel, Sunil ;
Boyer, David ;
Dugel, Pravin ;
Kherani, Saleema ;
Withers, Barbara ;
Gambino, Laura ;
Peters, Kevin ;
Brigell, Mitchell .
OPHTHALMOLOGY, 2016, 123 (08) :1722-1730
[10]   Treatment of Diabetic Macular Edema with an Inhibitor of Vascular Endothelial-Protein Tyrosine Phosphatase That Activates Tie2 [J].
Campochiaro, Peter A. ;
Sophie, Raafay ;
Tolentino, Michael ;
Miller, Daniel M. ;
Browning, David ;
Boyer, David S. ;
Heier, Jeffrey S. ;
Gambino, Laura ;
Withers, Barbara ;
Brigell, Mitchell ;
Peters, Kevin .
OPHTHALMOLOGY, 2015, 122 (03) :545-554